Abstract

Although voriconazole is recommended as a first-line treatment for patients with invasive pulmonary aspergillosis, its adverse event profile has

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call